Tags : Novel

Qiagen to Launch Viral RNA Epidemiology Test for COVID-19 and

Shots: Qiagen to launch the QIAprep&amp Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA viruses The kit combines a liquid-based sample preparation step completed in the only 2min. with real-time PCR detection in a streamlined workflow that can be automated with […]Read More

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will […]Read More

BMS Signs an Exclusive Option to License Agreement with Dragonfly

Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly’s platform for multiple new targets The focus of the agreement is to expand the collaboration b/w the companies […]Read More

BARDA to Fund $1B to AstraZeneca for Research and Development

Shots: The $1B support is for the development, production and delivery of the vaccine with its initiation in H2’20 including a P-III trial with 30,000 participants and a pediatric trial.AZ has initiated to provide wider access to University of Oxford’s vaccine and concluded to provide 400M doses has secured total manufacturing capacity for 1B doses […]Read More

Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel

Shots: Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates, discovered and developed under the agreement If Merck exercises its option, Skyhawk will receive an option fees, milestones and […]Read More

Novartis Signs an Agreement with Dyno to Develop Novel AVV

Shots: Dyno to receive upfront, research funding, license fees, clinical, regulatory & sales milestones and royalties on WW sales. The company will also utilize its AI technology & its suite of machine learning plus experimental tools for the designing and discovery of novel AAV capsids Novartis will be responsible for conducting pre-clinical, clinical trials including […]Read More

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific

Shots: The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing, whereas Aravive will be responsible for pre/ clinical development In 2018, Aravive and WuXi Biologics expanded their manufacturing collaboration for development and […]Read More

Incyte’s Pemazyre (pemigatinib) Receives the US FDA’s Approval as the

Shots: The approval is based on P-II FIGHT-202 (NCT02924376) study which involves assessing of Pemazyre (13.5 mg, qd) in adults with previously treated, locally advanced or metastatic cholangiocarcinoma with documented FGFR2 fusion or rearrangement The study has three cohorts: Cohort A (FGFR2 fusions or rearrangements), Cohort B (other FGF/FGFR genetic alterations) or Cohort C (no […]Read More

UroGen’s Jelmyto Receives the US FDA’s Expedited Approval as a

Shots: The approval is based on P-III OLYMPUS trial results assessing Jelmyto in 74 adults with LG UTUC to evaluate its safety, tolerability and tumor ablative effect across the US and Israel The study resulted in CR 58%, Kaplan-Meier analysis estimated 12-month durability at 84%, median duration of response has not been reached, no treatment-related […]Read More